Panaji Journal

Acute Respiratory Distress Syndrome Pipeline Booms as 60+ Companies likely to Enter in the Treatment Domain | Major Companies – Faron Pharmaceuticals, Athersys, and Others

 Breaking News
  • No posts were found

Acute Respiratory Distress Syndrome Pipeline Booms as 60+ Companies likely to Enter in the Treatment Domain | Major Companies – Faron Pharmaceuticals, Athersys, and Others

April 20
00:25 2023
Acute Respiratory Distress Syndrome Pipeline Booms as 60+ Companies likely to Enter in the Treatment Domain | Major Companies - Faron Pharmaceuticals, Athersys, and Others

DelveInsight’s, “Acute Respiratory Distress Syndrome Pipeline Insight 2023” report provides comprehensive insights about 60+ companies and 60+ pipeline drugs in the Acute Respiratory Distress Syndrome pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Key Takeaways from the Acute Respiratory Distress Syndrome Pipeline Report

 

  • Over 60+ Acute Respiratory Distress Syndrome companies are evaluating 60+ Acute Respiratory Distress Syndrome pipeline therapies in various stages of development, and their anticipated acceptance in the Acute Respiratory Distress Syndrome market would significantly increase market revenue.

 

  • The leading Acute Respiratory Distress Syndrome Companies include Faron Pharmaceuticals, BioMarck Pharmaceuticals, Athersys, Apeiron Biologics, Cynata Therapeutics, Orbsen Therapeutics, GEn1E Lifesciences, Exvastat, Longeveron, CohBar, ZyVersa Therapeutics, Abbreos, Aviceda Therapeutics, ImStem Biotechnology, Bayer, AVM Biotechnology, Cartesian Therapeutics, Sage Therapeutics, Roivant Sciences, ZyVersa Therapeutics, Aerpio Pharmaceuticals, and others.

 

  • Promising Acute Respiratory Distress Syndrome Pipeline Therapies to include MultiStem, TNX-832, HLCM051, ALT-836, Nitric Oxide, ECMO (Quadrox®, Jostra®, Maquet®), glenzocimab, and others.

 

  • The Acute Respiratory Distress Syndrome Companies and academics are working to assess challenges and seek opportunities that could influence Acute Respiratory Distress Syndrome R&D. The Acute Respiratory Distress Syndrome pipeline therapies under development are focused on novel approaches to treat/improve Acute Respiratory Distress Syndrome.

 

Request a sample and discover the recent breakthroughs happening in the Acute Respiratory Distress Syndrome Pipeline landscape @ Acute Respiratory Distress Syndrome Pipeline Outlook Report

 

Acute Respiratory Distress Syndrome Overview

Acute Respiratory Distress Syndrome is a life-threatening acute lung injury commonly resulting from sepsis, trauma, and severe pulmonary infections that allows fluid to leak into the lungs. The signs and symptoms of Acute Respiratory Distress Syndrome vary in intensity, depending on its cause and severity, including severe shortness of breath, unusual rapid breathing, low blood pressure, confusion and extreme tiredness.

 

Recent Developmental Activities in the Acute Respiratory Distress Syndrome Treatment Landscape

 

  • In February 2021, Athersys announced that it had entered into a cooperation agreement with HEALIOS. The cooperation agreement is intended to reaffirm the mutual commitment to the collaborative development of MultiStem in Japan.

 

  • In March 2021, Partner Therapeutics announced a licensing and collaboration agreement with SIRS Therapeutics and F4 Pharma to support the development of FX-06. This synthetic peptide has a broad spectrum of potential indications.

 

  • In June 2020, NeuroRx, in partnership with Relief Therapeutics, announced that the US FDA awarded Fast Track designation to NeuroRx for the investigation of RLF-100 (Aviptadil) for the treatment of acute lung injury/acute respiratory distress syndrome associated with COVID-19.

 

  • In December 2020, The Food and Drug Administration (FDA) granted Fast Track designation to remestemcel-L for the treatment of acute respiratory distress syndrome (ARDS) due to coronavirus disease 2019 (COVID-19).

 

  • In November 2020, Novartis announced that it entered into an exclusive worldwide license and collaboration agreement with Mesoblast to develop, commercialize and manufacture remestemcel-L to treat acute respiratory distress syndrome.

 

  • In September 2020, Dimerix was awarded USD 1 million from the Australian Government’s BTB program to support the inclusion of DMX-200 in the REMAP-CAP global study.

 

  • In September 2020, Athersys announced that MultiStem cell therapy was granted Regenerative Medicine Advanced Therapy (RMAT) designation from the US FDA for the acute respiratory distress syndrome (ARDS) program. In May 2019, US FDA granted Fast Track designation to MultiStem cell therapy for ARDS.

 

For further information, refer to the detailed Acute Respiratory Distress Syndrome Drugs Launch, Acute Respiratory Distress Syndrome Developmental Activities, and Acute Respiratory Distress Syndrome News, click here for Acute Respiratory Distress Syndrome Ongoing Clinical Trial Analysis

 

Acute Respiratory Distress Syndrome Emerging Drugs Profile

 

  • BIO-11006: BioMarck Pharmaceuticals

BIO-11006 is a novel peptide that inhibits the pro-inflammatory effects of overactive MARCKS protein. It is a ten-amino acid peptide that inhibits the phosphorylation of the MARCKS protein (myristoylated alanine rich protein kinase C substrate), which is a substrate for protein kinase C. BIO-11006 is in Phase II clinical studies for the treatment of Adult respiratory distress syndrome, chronic obstructive pulmonary disease, and Non-small cell lung cancer.

 

  • MultiStem: Athersys

MultiStem is an “”off-the-shelf”” stem cell product candidate, manufactured from Multipotent Adult Progenitor Cells. These cells are distinct from mesenchymal stem cells (MSCs) and other cell types. The drug is in Phase III clinical studies for the treatment of ischemic stroke and Acute Respiratory Distress Syndrome. The therapy has the equivalent of Fast Track status in Japan. In September 2020, Athersys announced that MultiStem cell therapy was granted Regenerative Medicine Advanced Therapy (RMAT) designation from the U.S. Food and Drug Administration (FDA) for the Acute Respiratory Distress Syndrome program.

 

Acute Respiratory Distress Syndrome Pipeline Therapeutics Assessment

There are approx. 60+ key companies which are developing the therapies for Acute Respiratory Distress Syndrome. The companies which have their Acute Respiratory Distress Syndrome drug candidates in the most advanced stage, i.e. Phase III include, Athersys.

 

Find out more about the Acute Respiratory Distress Syndrome Pipeline Segmentation, Therapeutics Assessment, and Acute Respiratory Distress Syndrome Emerging Drugs @ Acute Respiratory Distress Syndrome Treatment Landscape

 

Scope of the Acute Respiratory Distress Syndrome Pipeline Report

 

  • Coverage- Global

 

  • Acute Respiratory Distress Syndrome Companies- Faron Pharmaceuticals, BioMarck Pharmaceuticals, Athersys, Apeiron Biologics, Cynata Therapeutics, Orbsen Therapeutics, GEn1E Lifesciences, Exvastat, Longeveron, CohBar, ZyVersa Therapeutics, Abbreos, Aviceda Therapeutics, ImStem Biotechnology, Bayer, AVM Biotechnology, Cartesian Therapeutics, Sage Therapeutics, Roivant Sciences, ZyVersa Therapeutics, Aerpio Pharmaceuticals, and others.

 

  • Acute Respiratory Distress Syndrome Pipeline Therapies- MultiStem, TNX-832, HLCM051, ALT-836, Nitric Oxide, ECMO (Quadrox®, Jostra®, Maquet®), glenzocimab, and others.

 

  • Acute Respiratory Distress Syndrome Pipeline Segmentation: Product Type, Molecule Type, Route of Administration, Mechanism of Action

 

Dive deep into rich insights for drugs for Acute Respiratory Distress Syndrome Pipeline Companies and Therapies, click here @ Acute Respiratory Distress Syndrome Unmet Needs and Analyst Views

 

Table of Content

  1. Introduction
  2. Executive Summary
  3. Acute Respiratory Distress Syndrome: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Acute Respiratory Distress Syndrome – DelveInsight’s Analytical Perspective
  7. In-depth Commercial Assessment
  8. Acute Respiratory Distress Syndrome Collaboration Deals
  9. Late Stage Products (Phase III)
  10. Traumakine: Faron Pharmaceuticals
  11. Drug profiles in the detailed report…..
  12. Mid Stage Products (Phase II)
  13. BIO-11006: BioMarck Pharmaceuticals
  14. Drug profiles in the detailed report…..
  15. Early Stage Products (Phase I)
  16. GEn1E-1124: GEn1E Lifesciences
  17. Drug profiles in the detailed report…..
  18. Preclinical/Discovery Stage Products
  19. IC 100: ZyVersa Therapeutics
  20. Drug profiles in the detailed report…..
  21. Inactive Products
  22. Acute Respiratory Distress Syndrome Key Companies
  23. Acute Respiratory Distress Syndrome Key Products
  24. Acute Respiratory Distress Syndrome- Unmet Needs
  25. Acute Respiratory Distress Syndrome- Market Drivers and Barriers
  26. Acute Respiratory Distress Syndrome- Future Perspectives and Conclusion
  27. Acute Respiratory Distress Syndrome Analyst Views
  28. Acute Respiratory Distress Syndrome Key Companies
  29. Appendix

 

Got Queries? Find out the related information on Acute Respiratory Distress Syndrome Mergers and acquisitions, Acute Respiratory Distress Syndrome Licensing Activities @ Acute Respiratory Distress Syndrome Recent Trends, and Future Perspectives

 

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Related Articles